Use of (s)-3-amino-4-(difluoromethylene) cyclopent-1-en-1-carboxylic acid in treatment of multiple sclerosis
(S)-3-Amino-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid is a highly effective GABA-AT inhibitor that solves the problem of significant side effects of existing multiple sclerosis drugs by increasing GABA concentration in the brain, thereby effectively improving multiple sclerosis symptoms and reducing side effects.
Patent Information
- Application Number
- CN202480013278.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-17
- Filing Date
- 2024-02-16
- Publication Date
- 2025-09-16
AI Technical Summary
Existing drugs for the treatment of multiple sclerosis have significant side effects, are unable to effectively alleviate the symptoms of relapsing and progressive multiple sclerosis, and lack the ability of highly effective GABA-AT inhibitors to cross the blood-brain barrier.
(S)-3-Amino-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is a highly effective GABA-AT inhibitor that increases GABA concentration in the brain, inhibits the myelin-damaging inflammatory activity of lymphocytes and macrophages, reduces the production of inflammatory cytokines, and provides effective improvement in multiple sclerosis symptoms.
This compound significantly reduces the side effects associated with existing drugs while reducing the symptoms of multiple sclerosis, provides higher GABA-AT inhibition efficiency and the ability to cross the blood-brain barrier, and significantly improves vision, movement, sensory, urinary, intestinal, cognitive and psychiatric symptoms.